INTRODUCTION: Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases worldwide. Some researchers have suggested that the serum vitamin D (Vit D) level may relate to disease activity. The current study was designed to identify the correlation between vitamin D prescription and prevention of relapses in rheumatoid arthritis. PATIENTS AND METHOD: A double blinded, randomized controlled trial study was performed using 80 RA patients. RA was controlled and patients were in remission during the past 2 months. Serum level of Vit D in the studied patients was below 30 ng/dl. Patients were randomly allocated to receive Vit D or placebo. In the 6-month follow-up period, the Disease Activity Score 28 (DAS28) was used in case of relapses as an index of RA activity to compare the two groups. RESULTS: The flare rate was not different between two groups (p > 0.05). The odds ratio of the rate of decline in patients of the trial group compared with the control group was 1.17 (not significant; p > 0.05). The mean DAS28 between the two patient groups was not significant (p > 0.05). CONCLUSION: A low Vit D level was not identified to be a risk factor for RA severity or flare ups; however, although not statistically significant, Vit D treatment might be clinically effective. Further studies are needed with more emphasis on the issue of cost effectiveness and clinical importance to provide more information.
RCT Entities:
INTRODUCTION:Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases worldwide. Some researchers have suggested that the serum vitamin D (Vit D) level may relate to disease activity. The current study was designed to identify the correlation between vitamin D prescription and prevention of relapses in rheumatoid arthritis. PATIENTS AND METHOD: A double blinded, randomized controlled trial study was performed using 80 RA patients. RA was controlled and patients were in remission during the past 2 months. Serum level of Vit D in the studied patients was below 30 ng/dl. Patients were randomly allocated to receive Vit D or placebo. In the 6-month follow-up period, the Disease Activity Score 28 (DAS28) was used in case of relapses as an index of RA activity to compare the two groups. RESULTS: The flare rate was not different between two groups (p > 0.05). The odds ratio of the rate of decline in patients of the trial group compared with the control group was 1.17 (not significant; p > 0.05). The mean DAS28 between the two patient groups was not significant (p > 0.05). CONCLUSION: A low Vit D level was not identified to be a risk factor for RA severity or flare ups; however, although not statistically significant, Vit D treatment might be clinically effective. Further studies are needed with more emphasis on the issue of cost effectiveness and clinical importance to provide more information.
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Willem F Lems; Rob J van de Stadt; Margret H M T de Koning; Henk W Reesink; Moud R Habibuw; Irene E van der Horst-Bruinsma; Jos W R Twisk; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2006-11
Authors: M Cutolo; K Otsa; K Laas; M Yprus; R Lehtme; M E Secchi; A Sulli; S Paolino; B Seriolo Journal: Clin Exp Rheumatol Date: 2006 Nov-Dec Impact factor: 4.473
Authors: Z Andjelkovic; J Vojinovic; N Pejnovic; M Popovic; A Dujic; D Mitrovic; L Pavlica; D Stefanovic Journal: Clin Exp Rheumatol Date: 1999 Jul-Aug Impact factor: 4.473
Authors: Steven M Craig; Fang Yu; Jeffrey R Curtis; Graciela S Alarcón; Doyt L Conn; Beth Jonas; Leigh F Callahan; Edwin A Smith; Larry W Moreland; S Louis Bridges; Ted R Mikuls Journal: J Rheumatol Date: 2009-12-23 Impact factor: 4.666
Authors: André Silva Franco; Thiago Quadrante Freitas; Wanderley M Bernardo; Rosa Maria R Pereira Journal: Medicine (Baltimore) Date: 2017-06 Impact factor: 1.889